Compare FNWD & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | FNWD | IXHL |
|---|---|---|
| Founded | 1994 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Savings Institutions | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.0M | 97.6M |
| IPO Year | 1996 | 2024 |
| Metric | FNWD | IXHL |
|---|---|---|
| Price | $37.55 | $3.20 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $34.00 | N/A |
| AVG Volume (30 Days) | 4.5K | ★ 4.1M |
| Earning Date | 04-28-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.29% | N/A |
| EPS Growth | ★ 44.90 | N/A |
| EPS | ★ 1.42 | N/A |
| Revenue | N/A | ★ $12,000.00 |
| Revenue This Year | $17.40 | N/A |
| Revenue Next Year | $5.44 | N/A |
| P/E Ratio | $26.23 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.46 | $0.11 |
| 52 Week High | $39.99 | $6.39 |
| Indicator | FNWD | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 53.96 | 56.41 |
| Support Level | $35.25 | $0.31 |
| Resistance Level | $38.75 | $5.17 |
| Average True Range (ATR) | 0.94 | 0.51 |
| MACD | 0.07 | 0.09 |
| Stochastic Oscillator | 79.50 | 49.82 |
Finward Bancorp is a bank holding company, which engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Saving Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out through the United States.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.